EGFR and adenocarcinoma: As mentioned in the introduction section, the main possible reasons behind the failure of gefitinib and erlotinib studies in esophageal carcinoma were: no population screening was conducted, with most of the recruited subjects were diagnosed with adenocarcinoma, or no EGFR biomarker screening was performed.